Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAge Labs, Inc.BIOA · Entity 5569 | Director · Chief Operating Officer | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAge Labs, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2036-02-16 | Direct | 110,000 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 110,000 · Balance 110,000 F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2036-02-16 | IndirectBy Spouse | 12,500 |
Reported balance
After 2026-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-17 · Grant · Acquired 12,500 · Balance 12,500 F2: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date. F3: Represents an employee stock option directly held by the reporting person's spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date.
F3: Represents an employee stock option directly held by the reporting person's spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 19, 2026 21:40 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0002036289-26-000002 · form4-02192026_090237.xml · derivative · entry 2 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-02-16 F2 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date. F3 · ownership.nature: Represents an employee stock option directly held by the reporting person's spouse. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:40 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0002036289-26-000002 · form4-02192026_090237.xml · derivative · entry 1 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:21 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001415889-25-004864 · form4-02202025_090258.xml · derivative · entry 1 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 25, 2025 21:28 UTC Amendment | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001415889-25-005496 · form4a-02252025_090206.xml · derivative · entry 1 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. F2 · ownership.nature: Represents an employee stock option directly held by the reporting person's spouse. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:17 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 4,952 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024040 · form4-09272024_080956.xml · derivative · entry 1 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 4,952 Underlying: Common Stock · 4,952 shares Expires 2034-09-24 F1 · derivative.exercise_date: The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. F2 · ownership.nature: Represents an employee stock option directly held by the reporting person's spouse. Read SEC document |
| April 17, 2024 Filed Sep 27, 2024 20:17 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 13,598 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001415889-24-024040 · form4-09272024_080956.xml · derivative · entry 3 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 13,598 Underlying: Common Stock · 13,598 shares Expires 2034-04-16 F3 · date: This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). F5 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. F2 · ownership.nature: Represents an employee stock option directly held by the reporting person's spouse. Read SEC document |
| April 17, 2024 Filed Sep 27, 2024 20:17 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 257,973 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001415889-24-024040 · form4-09272024_080956.xml · derivative · entry 2 Morgen Eric · CIK 0002036289 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,973 Underlying: Common Stock · 257,973 shares Expires 2034-04-16 F3 · date: This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.